Serum proteomics identifies biomarkers for predicting non-survivors in elderly COVID-19 patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Following China
Area Of Science
- Gerontology
- Infectious Diseases
- Proteomics
Background
- China's cessation of the zero-COVID-19 policy in December 2022 led to increased COVID-19 hospitalizations and deaths, especially in the elderly.
- Accurate prediction of non-survivors is crucial for timely interventions and improved outcomes in elderly COVID-19 patients.
- Understanding prognostic factors aids in refining treatment strategies and guiding future research in this demographic.
Purpose Of The Study
- To characterize the proteomic profile of elderly COVID-19 patients in China.
- To identify key factors contributing to mortality in this population.
- To develop a predictive panel for survival outcomes.
Main Methods
- Serum proteome analysis using 4D- সার্বিক ডায়াগনস্টিক ইমেজিং (DIA) mass spectrometry.
- Comprehensive characterization of disease features in elderly Chinese COVID-19 patients.
- Validation of identified biomarkers using enzyme-linked immunosorbent assay (ELISA).
Main Results
- Immune disorders, lung damage, and cardiovascular disorders were identified as primary causes of death.
- Proteomic analysis demonstrated higher sensitivity than clinical indices in detecting these underlying disorders.
- A prediction panel comprising CXCL10, CXCL16, and IL1RA levels was established and validated for predicting survival outcomes.
Conclusions
- Proteomic profiling offers a sensitive approach to understanding COVID-19's impact on elderly patients.
- Specific biomarkers (CXCL10, CXCL16, IL1RA) can significantly enhance the prediction of survival outcomes.
- These findings support targeted interventions and improved clinical management for elderly COVID-19 patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
